ClinicalTrials.gg
CompletedNCT03319238OKAPIUpdated Nov 20, 2026

OBSERVATIONAL STUDY OF THE MANAGEMENT OF PATIENTS WITH CHRONIC PAIN

An observational study in Chronic Pain, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University Hospital, Clermont-Ferrand · Observational

How we know

Updated Nov 20, 2026Now CompletedResults publication added+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
585
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Chronic Pain by University Hospital, Clermont-Ferrand — 5 open to participants now, 6 under way, none of them phase 3. Chronic Pain · University Hospital, Clermont-Ferrand.

Enrollment
6th of 13
585 · median 501
Started
2016
with 2 others
Observational
13 of 22
2 open now
Registered
9th of 22
by date

Among the 22 studies in Chronic Pain by University Hospital, Clermont-Ferrand, this one is the 6th largest by enrollment of the 13 observational ones that give a count, is one of 3 that started in 2016, is one of 13 observational ones, and was the 9th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

5 of the 22 studies in Chronic Pain by University Hospital, Clermont-Ferrand are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Chronic Pain by University Hospital, Clermont-Ferrand, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the safety of use, benefits and risks of repeated use of ketamine for each patient with chronic pain in different structures of pain management.

Read the detailed description

This is an observational, longitudinal and multicenter study about use of ketamine. Benefits are assessed with pain intensity, anxiety, depression, quality of life and global impression of change. Risks are also assessed with adverse event collection.

03

Conditions studied

  • Chronic Pain

Keywords

  • Chronic pain
  • Neuropathic pain
  • Ketamine
  • Concomitant treatment
  • Adverse effect
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with chronic pain

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged over 18 years
  • Patients with chronic pain (more than 6 months)
  • Patients with peripheral or central neuropathic pain, fibromyalgia, algoneurodystrophy

Exclusion criteria

Exclusion Criteria:

  • Patient under 18 years of age,
  • Patient not requiring prescription of ketamine
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
585 participants (actual)
Patient registry
No

Groups and cohorts

  • Patient cohort

    Neuropathic pain patient taking ketamine

    Other: ketamine

Interventions

  • Otherketamine

    The aim of this study is to evaluate the safety of use, benefits and risks of repeated use of ketamine for each patient with chronic pain in different structures of pain management.

06

What researchers measure

Primary outcomes

  1. Descriptive analysis of benefit

    Benefits (pain release after ketamine use) will be assessed by the Pain by the Numerical Pain Rating Scale (NPRS): the scale ranges from 0 no pain to 10 maximal tolerable pain, and risks will be assessed by collecting the ketamine adverse events reported by the patient and by the physician.

    Time frame: At baseline

Secondary outcomes

  1. Descriptive analysis of risk (by collecting adverse event) of ketamine use.

    Biological statements will be collected during the usual care of patients, if possible (ASAT, ALAT, total bilirubin, conjugate bilirubin, free bilirubin, gamma glutamyl transferase, alkaline phosphatase,…)

    Time frame: At baseline

  2. Neuropathic Pain in 4 questions (DN4),

    The Neuropathic pain in 4 questions (DN4) at baseline only. DN4 is a clinical tool for the diagnosis of neuropathic pain. This questionnaire has four questions divided into 10 items related to the interview (ie, symptoms) and to the sensory examination (ie, signs). The investigator asks and examines the patient and notes a response "no" or "yes" for each item: "yes" is scored as "1" and "no" is scored as "0". The sum of scores gives the total score of the patient (/10). DN4 is considered as positive if the patient obtains a score of 4/10.

    Time frame: At baseline

  3. Patient Global Impression of Change, the characteristics of pain (PGIC)

    The Patient Global Impression of Change is a scale of global perception of change ("Deterioration" or "Improvement") realized at each telephone call except for baseline. This scale is graduated from 1 = very strongly improved to 7 = very strongly aggravated

    Time frame: At baseline

  4. Emotional status by Hospital Anxiety and Depression scale (HAD)

    The HAD scale is a self-administered questionnaire in 14 items completed by the patient. It is used to determine the levels of anxiety and depression. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression. Global score ranges from 0 to 42.

    Time frame: At baseline

  5. Quality of life (Short Form 12 items Short Form survey)

    assessed by a quality of life questionnaire (Short Form 12 items Short Form survey (SF12)

    Time frame: At baseline

07

Study locations

1 site
  • CHU Clermont-Ferrand
    Clermont-Ferrand, 63003, France
08

References and documents

Publications

  • Pickering G, Voute M, Sorel M, Pereira B, Riant T. Sex and Age Differences in Ketamine Efficacy and Safety in Chronic Pain Alleviation. J Clin Med. 2025 Jun 16;14(12):4269. doi: 10.3390/jcm14124269. PubMed 40566014 ↗
  • Corriger A, Voute M, Lambert C, Pereira B, Pickering G; OKAPI Consortium. Ketamine for refractory chronic pain: a 1-year follow-up study. Pain. 2022 Apr 1;163(4):690-701. doi: 10.1097/j.pain.0000000000002403. PubMed 34252909 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Sep 2017, 14 months.

Of 337 non-industry observational studies under Chronic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 56. This study's 14 months is below that.

Counting every sponsor, half of 363 studies reached it within 24 months; a quarter within 12 and three quarters within 56.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2018 → Sep 2017, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2017
First posted
Oct 24, 2017
StartActual
Jul 7, 2016
Primary completionActual
Sep 21, 2017was Sep 2018
CompletionActual
Nov 1, 2018
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 20, 2026
Primary completion
Sep 1, 2018→Sep 21, 2017 (actual)
Nov 20, 2026
Enrollment
1000 (estimated)→585 (actual)
Nov 20, 2026
Publications
Results publication added: Pickering G, Voute M, Sorel M, Pereira B, Riant T. Sex and Age Differences in Ketamine Efficacy and Safety in Chronic Pain Alleviation. J Clin Med. 2025 Jun 16… PubMed 40566014 ↗
Nov 20, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionDescriptive analysis of risk (by collecting adverse event) of ketamine use.: how it is measured was reworded
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Status unknown→Completed
    Publications Results publication added: Pickering G, Voute M, Sorel M, Pereira B, Riant T. Sex and Age Differences in Ketamine Efficacy and Safety in Chronic Pain Alleviation. J Clin Med. 2025 Jun 16… PubMed 40566014 ↗
    Primary completion Sep 1, 2018→Sep 21, 2017 (now actual)
    Enrollment 1000 (estimated)→585 (actual)
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionDescriptive analysis of risk (by collecting adverse event) of ketamine use.: how it is measured was reworded
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03319238
Responsible party
Sponsor
First posted
Oct 24, 2017
Start date
Jul 7, 2016
Primary completion
Sep 21, 2017
Completion
Nov 1, 2018
Last update
Nov 20, 2026

Study contacts

Gisèle PICKERING
principal investigator · University Hospital, Clermont-Ferrand

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion